Table 1 Recommended antiretroviral dosing for children aged 2-12 years used in this analysis8

Committees and participants (alphabetical)


Table 1 Recommended antiretroviral dosing for children aged 2-12 years used in this analysis8

 

Growth
parameter

Minimum recommended daily dose8

Maximum daily

dose prescribed (usually adult dose)

Weight / SA at which maximum dose

reached

Median age of children in CHIPS

at weight/SA for maximum dose

(years)

NRTI

     

zidovudine

m2

360mg/m2

600mg

1.67m2

14.7

lamivudine

kg

8mg/kg

300mg

37.5kg

11.9

abacavir

kg

16mg/kg

600mg

37.5kg

11.9

didanosine

m2

180mg/m2 *

400mg if >60kg

400mg

2.22m2

60kg

16.8
15.0

stavudine

kg

2mg/kg
60mg if 30-60kg

80mg if >60kg

80mg

60kg

15.0

tenofovir

kg

6mg/kg

300mg

50kg

13.9

NNRTI

     

nevirapine

m2

300mg/m2 *

400mg

1.33m2

12.6

efavirenz

kg

12.5mg/kg †

600mg

48kg

13.2

PI

     

lopinavir
/ritonavir

m2

460/115mg/m2 *‡

800/200mg

1.74m2

15.4

nelfinavir

kg

110mg/kg

2500mg

22.7kg

7.3

ritonavir

m2

700mg/m2

1200mg

1.71m2

15.1

* the lower limit of the range of doses included in guidelines

† approximate dose for weight, based on the more complex formula 600*(weight/70)0.7 used in the original study11. Higher doses are recommended for syrup (approx 15mg/kg), and licensed dosing is based on weight bands (corresponding to a wider range of doses per kilo): 13-<15kg 200mg, 15-<20kg 250mg, 20-<25kg 300mg, 25-<32.5kg 350mg, 32.5-40kg 400mg, >40kg 600mg. Formulation data are not collected in CHIPS.

‡ higher doses are recommended if taken concurrently with NNRTI.

Note: shaded boxes denote current best dose where approved paediatric dose has not yet been licensed. SA = surface area.

 

 

Committees and participants (alphabetical):

CHIPS Steering Committee: K Butler, K Doerholt, D Dunn, T Duong, D Gibb, H Lyall, J Masters, E Menson, V Novelli, C Peckham, A Riordan, M Sharland, P Tookey, G Tudor-Williams, G Wait

National Study of HIV in Pregnancy & Childhood, Institute of Child Health: Janet Masters, Catherine Peckham, Pat Tookey

MRC Clinical Trials Unit: D Dunn, T Duong, L Farrelly, D Gibb, D Johnson, E Menson, G Wait, AS Walker

We thank the staff, families & children from the CHIPS centres:

Republic of Ireland: Our Lady's Hospital for Sick Children, Dublin: K Butler, M O'Meara, A Walsh

UK: Heartlands Hospital, Birmingham: A Riordan; Bristol Royal Hospital for Children, Bristol: A Finn, A Foot, L Hutchison, Ninewells Hospital and Medical School, Dundee: T Lornie; Ealing Hospital, Middlesex: K Sloper, V Shah; Royal Edinburgh Hospital for Sick Children, Edinburgh: J Mok; Great Ormond St Hospital for Children, London: DM Gibb, V Novelli, N Klein, S Fasolo, M Clapson, B Ohene-Kena, J Flynn, K Moshal; King's College Hospital, London: C Ball, D Nayagam, S Hawkins; Newham General Hospital, London: S Liebeschuetz, E Cooper, D Shingadia, T Fisher, S Wong, Northampton General Hospital, Northhampton: F Thompson; Royal Free Hospital, London: V Van Someren, S McKenna; St George's Hospital, London: M Sharland, R Chakraborty, S Donaghy, S Storey, C Wells; St Mary's Hospital, London: G Tudor-Williams, H Lyall, S Walters, S Campbell, C Hanley, C Walsh; St Thomas' Hospital, London: G Du Mont, R Cross; University Hospital Lewisham, London: J Stroobant; John Radcliffe Hospital, Oxford: A Pollard, S Segal; Sheffield Children's Hospital, Sheffield: F Shackley, J Hobbs; Chelsea and Westminster Hospital, London: H Lyall, P Seery; North Middlesex Hospital, London: H Lyall, J Daniels, B Sampson-Davis; University Hospital of Wales, Cardiff: B O' Hare; Royal London Hospital, London: D Shingadia, B Ramaboea; Northwick Park Hospital, Middlesex: A Williams, M Le Provost; Central Middlesex Hospital, London: A Williams, M Le Provost; Wexham Park, Slough: R Jones